A development stage biotechnology company focused on personalized cell therapies combines stem cell biology with the latest artificial intelligence and genomic approaches to investigate patient-specific, restorative treatments.
The biotech adopted the Sapio Platform in 2023, which incorporates the Sapio LIMS and Sapio ELN into a modern, unified informatics platform, and embarked on a 3-phase integration project to manage its exponential data growth.